Titan Hopes To Tap Into Niche Drug Addiction Market With Six-Month Implant
This article was originally published in The Pink Sheet Daily
Titan says compliance and abuse-resistance will hook payers on new long-acting formulations vs. low-cost generics.
You may also be interested in...
Acute alcohol intoxication is an unmet medical need that can be both lethal and a cost drain for the health care system, Aldea says. It plans to develop its lead candidate, an ALDH-2 activator, for the rare genetic disorder Fanconi anemia as well.
FDA provides a “road map” for potential sponsors of nonclinical and clinical trials of the opioid overdose treatment.
Company does not plan to compete against market-leading Suboxone, and will initially target the newly addicted, such as young adults, and certain professionals who can't take available treatments.